To compare the efficacy of XDEMVY ophthalmic drop to its vehicle control for the treatment of Demodex blepharitis and its impact on the soft contact lens wearing experience.

Start Date27 Dec 2023

Sponsor / Collaborator

Tarsus Pharmaceuticals, Inc.

NCT06054217

/ Active, not recruitingPhase 2

Evaluating the Effect of Two Dosing Regimens of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex Lid Infestation

The purpose of this study is to evaluate and compare the effect of two dosing regimens, BID versus TID dosing, of an Exploratory Vehicle (EV) on meibomian gland dysfunction (MGD) in patients with Demodex lid infestation.

Start Date01 Aug 2023

Sponsor / Collaborator

Tarsus Pharmaceuticals, Inc.

NCT05838170

/ CompletedPhase 2

A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of TP-04 in Participants With Papulopustular Rosacea

This study is being done to evaluate the safety, tolerability, and efficacy of the study drug, TP-04, in participants with papulopustular rosacea (PPR).

Start Date01 Mar 2023

Sponsor / Collaborator

Tarsus Pharmaceuticals, Inc.

100 Clinical Results associated with Lotilaner

100 Translational Medicine associated with Lotilaner

100 Patents (Medical) associated with Lotilaner

Literatures (Medical) associated with Lotilaner

01 Mar 2025·Ophthalmology and Therapy

Safety and Efficacy of Lotilaner Ophthalmic Solution (0.25%) in Treating Demodex Blepharitis: Pooled Analysis of Two Pivotal Trials

Article

Author: Dhamdhere, Kavita ; Simmons, Blake ; Peterson, Jared D ; Whitson, William E ; Boehmer, Blair E ; Berdy, Gregg J ; Neervannan, Sesha ; Yeu, Elizabeth ; Meyer, John ; Ciolino, Joseph B ; Paauw, James D ; Whitley, Walter O ; Periman, Laura M ; Koetting, Cecelia ; Bloomenstein, Marc R ; Vollmer, Patrick

INTRODUCTION:

Lotilaner ophthalmic solution (0.25%) is the first United States Food and Drug Administration (US FDA)-approved drug for treating Demodex blepharitis. In pivotal trials, it was found to be well tolerated and demonstrated a significant reduction in collarettes and mite density after a 6-week treatment regimen. This study aimed to report the safety and efficacy profile of lotilaner ophthalmic solution (0.25%) from a pooled analysis of two pivotal trials in patients with Demodex blepharitis.

METHODS:

Pooled data were analyzed from two randomized, double-masked, vehicle-controlled clinical trials [phase 2b/3 Saturn-1 (NCT04475432) and phase 3 Saturn-2 (NCT04784091)] in which patients with Demodex blepharitis were randomly assigned in a 1:1 ratio to receive either lotilaner ophthalmic solution (0.25%) (study group) or the vehicle formulation without lotilaner (control group), twice daily for 6 weeks. The outcome measures were the proportion of patients with 0-2 collarettes (grade 0 collarettes), mite eradication, erythema cure, and the proportion of patients with ≤ 10 collarettes (grade 0 or 1 collarettes) at day 43.

RESULTS:

Overall, 833 participants were randomized to receive either the study drug (N = 415) or vehicle (N = 418). On day 43, 49.8% of patients in the study group vs. 9.9% in the control group (p < 0.0001) had collarette grade 0 (0-2 collarettes). A reduction to ≤ 10 collarettes (grade 0 or 1 collarettes) was achieved in 85.1% of patients in study group vs. 28.0% in control group (p < 0.0001). The proportion of patients achieving mite eradication (60.2% vs. 16.1%, p < 0.0001) and erythema cure (24.9% vs. 7.9%, p < 0.0001) were also statistically significantly higher in the study group compared to the control group. The rates of adverse events were low in both studies, with no serious drug-related ocular adverse events reported. As many as 92% of patients rated the study drop as neutral to very comfortable.

CONCLUSIONS:

Twice-daily treatment with lotilaner ophthalmic solution (0.25%) for 6 weeks demonstrated statistical significance for all outcome measures compared to the vehicle control, with low rates of adverse events and a high rate of drop comfort.

01 Feb 2025·EXPERIMENTAL PARASITOLOGY

Efficacy of lotilaner for treating rabbits naturally infested by Psoroptes ovis and Leporacarus gibbus, in Rio de Janeiro, Brazil

Article

Author: Scott, Fabio B ; Lopes, Natália L ; Campos, Diefrey R ; Borges, Debora A ; Machado, Marília A ; Fernandes, Julio I

The aim of this study was to evaluate the efficacy of a single 20 mg/kg dose of lotilaner for treating rabbits with concomitant infection by P. ovis and L. gibbus. Fourteen rabbits with diagnoses of otitis and fur infection, caused respectively by P. ovis and L. gibbus, were included. Samples of otic crust were collected with tweezers, weighed and examined microscopically to identify ectoparasites, which were counted to determine the number of mites per gram of crust. Hair samples were collected from three areas of 1 cm² in different regions of the body, for examination under a stereomicroscope to determine occurrences of the mite L. gibbus. The animals in the treated group received a single oral dose of 20 mg/kg of lotilaner and were evaluated on days 0, +3, +7, +14, +21, +28 and + 35. Parasitological efficacy of 100% for controlling P. ovis was observed after seven days. Total clinical remission was reached 14 days after treatment. For L. gibbus, parasitological cure was obtained seven days after treatment. We concluded that a single dose of lotilaner was effective for controlling P. ovis and L. gibbus, leading to parasitological control and clinical improvement of the animals.

30 Dec 2024·Journal of Chinese Pharmaceutical Sciences

Efficacy and safety of lotilaner ophthalmic solution in the treatment of Demodex Blepharitis: a meta-analysis of randomized controlled trials

Author: Lu, Xiaojing ; Zhang, Qiwen ; Yang, Yongjie ; Lu, Jingli ; Liu, Kefeng ; Zhou, Qi ; Yang, Jing ; Kang, Jian

In this meta-anal., our aim was to systematically evaluate the efficacy and safety of lotilaner ophthalmic solution in treating Demodex Blepharitis (DB), with the goal of providing evidence for clin. practice.PubMed, Embase, Web of Science, The Cochrane Library, CNKI, Wanfang, and CBM were searched from inception to Nov. 28, 2023.Randomized controlled trials (RCTs) comparing lotilaner ophthalmic solution (exptl. group) with placebo (control group) for the treatment of DB were included.Two researchers independently screened the literature, extracted the data, and assessed the quality of the included studies.Meta-anal. was conducted using RevMan 5.4 software.The Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach was used to evaluate the evidence quality of outcomes.Publication bias was assessed using a funnel plot.Four RCTs involving 947 patients were included.Meta-anal. revealed that compared to placebo, lotilaner ophthalmic solution significantly increased the rate of mite eradication (RR=3.61, 95% CI (2.90, 4.49), P<0.00001).Addnl., lotilaner treatment resulted in higher rates of collarette cure, erythema cure, composite erythema/collarette cure, and clin. meaningful collarette cure; the differences were statistically significant, with effect sizes (RR=5.74, 95% CI (4.27, 7.72), P<0.00001), (RR=3.16, 95% CI (2.18, 4.58), P<0.00001), (RR=6.75, 95% CI (3.75, 12.16), P<0.00001), and (RR=3.09, 95% CI (2.65, 3.60), P<0.00001), resp.Mite d. (MD=-1.42, 95% CI (-2.09, -0.74), P<0.0001) and collarette grade (MD=-1.51, 95% CI (-1.77, -1.25), P<0.00001) were significantly reduced.Indeed, no discernible discrepancies in the comfort levels experienced with eye drops emerged between the two groups.Although the exptl. group did exhibit a slightly higher occurrence of treatment-related adverse events, ranging from instillation site discomfort to eye discharge and eyelid swelling, these variances did not attain statistical significance.Notably, upon GRADE evaluation, the study′s evidence quality was deemed moderate, while scrutiny for publication bias revealed minimal indications thereof.In the realm of treatment, lotilaner ophthalmic solution shined as a beacon of efficacy, effectively combating mite infections and bolstering cure rates among patients with DB. Moreover, its administration was met with commendable compliance and upheld safety standards

News (Medical) associated with Lotilaner

14 Mar 2025

·endpts.com

Altimmune to put its incretin into addiction trials; Tarsus aims to raise $125M

Plus, news about Heidelberg, Accropeutics, Allarity Therapeutics, Cadrenal and Inovio: Altimmune to test its incretin in addiction : Following the path set by Novo Nordisk last week , Altimmune said Thursday at its R&D Day that it plans to begin trials of its injectable GLP-1/glucagon agonist pemvidutide in alcohol use disorder as well as alcoholic liver disease. Stifel analysts wrote in a note on Thursday that Altimmune has animal data that suggest pemvidutide could reduce daily alcohol intake by around half. They also cautioned that additional data would be needed to validate the hypothesis. — Elizabeth Cairns Tarsus Pharmaceuticals’ expected $125 million stock sale: The drugmaker said the funds from the public offering will be used to support the US commercialization of Xdemvy, eye drops for irritation caused by tiny mites. Tarsus also said the funds will be used to advance its experimental ocular rosacea and lyme disease drugs. — Lei Lei Wu Heidelberg amends royalty deal: The company signed an agreement with HealthCare Royalty a year ago to provide royalties to Zircaix, or TLX250-CDx, an imaging agent for some kidney cancers. While the total value of the milestones remains the same at $90 million, the companies changed the deal so that Heidelberg will receive $20 million immediately rather than get $15 million as a sales milestone. They also reduced the FDA approval milestone to $70 million from $75 million. (That milestone will be further reduced if approval comes after 2025.) Heidelberg licensed the drug to Telix in 2017, and a rolling FDA submission was initiated in 2023. — Max Gelman Accropeutics raises $12M to fund IBD asset : The Series B-plus round was led by Shenzhen Capital Group and is set to extend the biotech’s cash runway into the second half of next year. The proceeds will be used for the ongoing Phase 1b trial of Accropeutics’ RIPK2 inhibitor, known as AC-101, in ulcerative colitis. Accropeutics also has a mid-stage TYK2/JAK1 inhibitor in development for psoriasis and a RIPK1 inhibitor for graft-versus-host disease. — Elizabeth Cairns Allarity Therapeutics settles with SEC: The company will pay $2.5 million to the Securities and Exchange Commission after the regulator alleged Allarity executives concealed from investors that the FDA had recommended against approving dovitinib, an experimental cancer therapy. The company did not admit or deny the allegations. — Jaimy Lee Cadrenal is still seeking a partner for tecarfarin: It wants help advancing the oral vitamin K antagonist into a pivotal trial for patients with left ventricular assist devices and other rare cardiovascular conditions. — Jaimy Lee Inovio’s DNA therapy is durable in early trial : The company said Thursday that a Phase 1 trial proves the concept of its so-called DMAbs. The DNA plasmids encoding antibodies derived from Evusheld, AstraZeneca’s Covid-19 prophylactic, were given to patients and were translated into the proteins by the patient’s own cells. All subjects who reached week 72 had biologically relevant levels of the antibodies, according to Inovio, and the expressed DMAbs bound to the SARS-CoV-2 spike protein confirmed functional activity. However, the company did not say whether the approach prevented infections . — Elizabeth Cairns

Phase 1Clinical Result

12 Mar 2025

·www.globenewswire.com

Tarsus Announces Proposed $100.0 Million Public Offering

IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the commencement of an underwritten public offering of $100.0 million of shares of its common stock. Tarsus also intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of its common stock offered in the proposed offering. All shares in the proposed offering are to be sold by Tarsus. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Goldman Sachs & Co. LLC, BofA Securities, Barclays, and Oppenheimer & Co. are acting as joint book-running managers for the offering. A registration statement relating to the shares to be sold in the proposed offering was filed with the U.S. Securities and Exchange Commission (“SEC”) on February 29, 2024 and became automatically effective upon filing. Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov. The offering will be made only by means of prospectus. A preliminary prospectus supplement related to the offering (including the accompanying prospectus) will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus may also be obtained, when available, from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@bofa.com; Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at (888) 603-5847, or by email at Barclaysprospectus@broadridge.com; or Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, New York 10004, by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these shares, nor shall there be any sale of these shares in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY (lotilaner ophthalmic solution, 0.25%) is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. Forward-Looking StatementsStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words, without limitation, “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors; including, but not limited to, risks and uncertainties related to market conditions, and satisfaction of customary closing conditions related to the proposed public offering and the grant to the underwriters of an option to purchase additional shares. Further, there are other risks and uncertainties that could cause actual results to differ from those set forth in the forward-looking statement and they are detailed from time to time in the reports Tarsus files with the Securities and Exchange Commission, including Tarsus’ Form 10-K for the year ended December 31, 2024 filed on February 25, 2025 with the SEC, copies of which are posted on its website and are available from Tarsus without charge. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained in this press release are based on the current expectations of Tarsus’ management team and speak only as of the date hereof, and Tarsus specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Contacts:Media Contact:Adrienne KempSr. Director, Corporate Communications(949) 922-0801akemp@tarsusrx.com Investor Contact:David NakasoneHead of Investor Relations(949) 620-3223DNakasone@tarsusrx.com

Drug Approval

12 Mar 2025

·ir.tarsusrx.com

Tarsus Announces Pricing of Upsized $125.0 Million Public Offering

IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of an upsized underwritten public offering of 2,808,988 shares of its common stock at a public offering price of $44.50 per share. In addition, Tarsus has granted the underwriters a 30-day option to purchase up to an additional 421,348 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Tarsus, are expected to be approximately $125.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on March 14, 2025, subject to the satisfaction of customary closing conditions. Goldman Sachs & Co. LLC, BofA Securities, Barclays, and Oppenheimer & Co. are acting as joint book-running managers for the offering. A registration statement relating to the shares to be sold in the offering was filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 29, 2024 and became automatically effective upon filing. Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov. The offering is being made only by means of a prospectus supplement and the accompanying prospectus which forms a part of the effective shelf registration statement. A preliminary prospectus supplement related to the offering (including the accompanying prospectus) has been filed with the SEC and is available on the SEC’s website located at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus may also be obtained, when available, from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@bofa.com; Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at (888) 603-5847, or by email at Barclaysprospectus@broadridge.com; or Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, New York 10004, by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these shares, nor shall there be any sale of these shares in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Tarsus Pharmaceuticals, Inc. Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY (lotilaner ophthalmic solution, 0.25%) is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words, without limitation, “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering. Further, there are other risks and uncertainties that could cause actual results to differ from those set forth in the forward-looking statement and they are detailed from time to time in the reports Tarsus files with the Securities and Exchange Commission, including Tarsus’ Form 10-K for the year ended December 31, 2024, filed on February 25, 2025, with the SEC, copies of which are posted on its website and are available from Tarsus without charge. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained in this press release are based on the current expectations of Tarsus’ management team and speak only as of the date hereof, and Tarsus specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Contacts: Media Contact Adrienne Kemp Sr. Director, Corporate Communications (949) 922-0801 AKemp@tarsusrx.com Investor Contact: David Nakasone Head of Investor Relations (949) 620-3223 DNakasone@tarsusrx.com

Drug Approval

100 Deals associated with Lotilaner

External Link

KEGG	Wiki	ATC	Drug Bank
-	Lotilaner	-	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Blepharitis	United States	Tarsus Pharmaceuticals, Inc.	24 Jul 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Infestation by Demodex	Phase 3	United States	Tarsus Pharmaceuticals, Inc.	29 Apr 2021
Lyme Disease	Phase 2	United States	Tarsus Pharmaceuticals, Inc.	14 Mar 2023
Rosacea	Phase 2	Canada	Tarsus Pharmaceuticals, Inc.	01 Mar 2023
Meibomian Gland Dysfunction	Phase 2	United States	Tarsus Pharmaceuticals, Inc.	03 Aug 2022
Malaria	Phase 1	United States	Tarsus Pharmaceuticals, Inc.	18 Jun 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05387083 (Corporate Publications) Manual	Phase 2	Lyme Disease	-	lotilaner high dose	nzivkwgoyt(ufitewvzrf) = yttffrwqmn lxiqwgcrlc (uisokkicvm, 1.4) View more	Positive	22 Feb 2024
				lotilaner low dose	nzivkwgoyt(ufitewvzrf) = fmklxpifia lxiqwgcrlc (uisokkicvm, 6.3) View more
NCT04475432 (Saturn-1, CTgov)	Phase 2/3	Infestation by Demodex \| Blepharitis	421	TP-03, 0.25% (Active)	lhlowroyaq(ezvqglgqal) = tjyesfmkle rzdlgyijao (fctgdopmyc, 0.034) View more	-	21 Dec 2023
				TP-03 Vehicle (Control)	lhlowroyaq(ezvqglgqal) = askqxyuzhu rzdlgyijao (fctgdopmyc, 0.018) View more
NCT04784091 (Saturn-2, CTgov)	Phase 3	Infestation by Demodex \| Blepharitis	412	TP-03 (Active)	oxtsjlcost(anufdsjafv) = vdzggvljhz fszxxsvrun (xndgntqafb, 0.035) View more	-	21 Dec 2023
				TP-03 Vehicle (Control)	oxtsjlcost(anufdsjafv) = mlmxbxdqzd fszxxsvrun (xndgntqafb, 0.023) View more
CTR20220726 \| NCT05629390 (LIBRA, GlobeNewswire) Manual	Phase 3	Infestation by Demodex	-	TP-03	afkwuvxrjk(pgrpcoiijk) = Results demonstrated statistically significant mite eradication in patients jfujbwjckf (ikvkayexsk ) View more	Positive	30 Oct 2023
				vehicle
NCT04784091 (Saturn-2, Pubmed \| Ophthalmology)	Phase 3	Infestation by Demodex	-	Lotilaner Ophthalmic Solution 0.25%	sdkqaesdqj(hssummrrkd) = vxpmhgitkx izxwfrzjbu (bfpdugkohu ) View more	Positive	01 Oct 2023
				Lotilaner Ophthalmic Solution 0.25% (Vehicle without Lotilaner)	sdkqaesdqj(hssummrrkd) = rkzcseestu izxwfrzjbu (bfpdugkohu ) View more
NCT04475432 \| NCT04784091 (Saturn-2, FDA) Manual	Not Applicable	Blepharitis	833	XDEMVY	hmletjkpsp(iiexzojqvo) = The most common ocular adverse reaction observed in controlled clinical studies with XDEMVY was instillation site stinging and burning which was reported in 10% of patients. Other ocular adverse reactions reported in less than 2% of patients were chalazion/hordeolum and punctate keratitis. fysotivhvd (erxemgylxb ) View more	Positive	24 Jul 2023
				Vehicle
NCT04475432 (Saturn-1, Pubmed)	Phase 2/3	Infestation by Demodex	421	Lotilaner ophthalmic solution, 0.25%	hualpfgnbn(nqjcrvnqbu) = All ocular adverse events in the study group were mild, with the most common being instillation site pain. tnlqppossp (ubebonzpdl )	Positive	11 Aug 2022
				Vehicle without lotilaner
NCT04784091 (Saturn-2, GlobeNewswire) Manual	Phase 3	Infestation by Demodex	412	Lotilaner	hinzmzuerx(uyccbncrkt) = hlbmedawxz yvgptekwhb (piascnulle ) View more	Positive	02 May 2022
				Placebo	hinzmzuerx(uyccbncrkt) = ehyfhhyfbr yvgptekwhb (piascnulle ) View more
ARVO2021	Phase 2	Infestation by Demodex	-	Lotilaner Ophthalmic Solution 0.25%	jelnyfunrt(cbxwhvjguc) = zurpwccnsx strzckviaa (dwoklzhewl ) View more	-	01 Jun 2021
				Vehicle	jelnyfunrt(cbxwhvjguc) = zwjmfaovtr strzckviaa (dwoklzhewl ) View more
Mars Study (ARVO2020)	Not Applicable	-	15	TP-03 0.25%	ahzqhbsugr(rpyevqpzyo) = No treatment-related adverse events were reported vteojnbeyd (hjlhigicki )	Positive	01 Jun 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis